ES2477497T3 - Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo - Google Patents

Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo Download PDF

Info

Publication number
ES2477497T3
ES2477497T3 ES08731126.2T ES08731126T ES2477497T3 ES 2477497 T3 ES2477497 T3 ES 2477497T3 ES 08731126 T ES08731126 T ES 08731126T ES 2477497 T3 ES2477497 T3 ES 2477497T3
Authority
ES
Spain
Prior art keywords
cancer
her3
her2
antibody
para
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08731126.2T
Other languages
English (en)
Spanish (es)
Inventor
Lukas C. Amler
Merrill Birkner
Chin-Yu Lin
Joachim Moecks
Andreas Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39599019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2477497(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2477497T3 publication Critical patent/ES2477497T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B61/00—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages
    • B65B61/20—Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for adding cards, coupons or other inserts to package contents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
ES08731126.2T 2007-03-02 2008-02-29 Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo Active ES2477497T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29748 1993-03-11
US89264007P 2007-03-02 2007-03-02
US892640P 2007-03-02
US91205307P 2007-04-16 2007-04-16
US912053P 2007-04-16
US2974808P 2008-02-19 2008-02-19
PCT/US2008/055502 WO2008109440A2 (en) 2007-03-02 2008-02-29 Predicting response to a her dimerisation inhibitor based on low her3 expression

Publications (1)

Publication Number Publication Date
ES2477497T3 true ES2477497T3 (es) 2014-07-17

Family

ID=39599019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08731126.2T Active ES2477497T3 (es) 2007-03-02 2008-02-29 Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo

Country Status (21)

Country Link
US (5) US7981418B2 (enExample)
EP (2) EP2132573B1 (enExample)
JP (4) JP2010520225A (enExample)
KR (2) KR20090115980A (enExample)
CN (2) CN103432580A (enExample)
AR (1) AR065589A1 (enExample)
AU (1) AU2008223069B2 (enExample)
BR (1) BRPI0808418A2 (enExample)
CA (1) CA2677108A1 (enExample)
CL (1) CL2008000614A1 (enExample)
CO (1) CO6220870A2 (enExample)
DK (1) DK2132573T3 (enExample)
ES (1) ES2477497T3 (enExample)
IL (1) IL199989A (enExample)
MX (1) MX2009008981A (enExample)
NZ (1) NZ578824A (enExample)
PE (1) PE20090681A1 (enExample)
PL (1) PL2132573T3 (enExample)
SI (1) SI2132573T1 (enExample)
TW (1) TWI352199B (enExample)
WO (1) WO2008109440A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
UA90480C2 (uk) * 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
US20110306514A1 (en) * 2009-01-14 2011-12-15 United States Department of Health and Human Services Ratio based biomarkers and methods of use thereof
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
AU2011242990B2 (en) * 2010-04-19 2015-02-12 Biomarker Strategies, Llc. Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012097368A2 (en) * 2011-01-14 2012-07-19 Response Genetics, Inc. Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
USD801353S1 (en) * 2014-09-11 2017-10-31 Express Scripts, Inc. Display screen with a graphical user interface
USD791796S1 (en) * 2014-09-11 2017-07-11 Express Scripts, Inc. Display screen with a graphical user interface
USD791797S1 (en) * 2014-09-11 2017-07-11 Express Scripts, Inc. Display screen with a graphical user interface
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US11275087B2 (en) * 2016-11-11 2022-03-15 Konica Minolta, Inc. Test support method for supporting prediction of pathological complete response (pCR) using fluorescent nanoparticles
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
US10208357B2 (en) 2017-03-21 2019-02-19 Medical Diagnostic Laboratories, Llc Cell based assay
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
US12040058B2 (en) * 2019-01-17 2024-07-16 Flatiron Health, Inc. Systems and methods for providing clinical trial status information for patients
WO2021232057A1 (en) * 2020-05-12 2021-11-18 Institut D'investigacions Biomediques August Pi Isunyer (Idibaps) Methods for breast cancer treatment and prediction of therapeutic response
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
AU2021308283A1 (en) 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations

Family Cites Families (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ATE130873T1 (de) 1988-04-18 1995-12-15 Applied Biotechnology Inc Nachweis der expression von neu genen und produkten.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
DE69033842T2 (de) 1989-08-04 2002-06-20 Schering Ag Äusserliche domäne von c-erbb-2:gp75
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5288477A (en) 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
AU3236793A (en) 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
WO1994009022A1 (en) 1992-10-09 1994-04-28 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
CA2175893C (en) 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0711565B1 (en) 1994-11-10 1998-08-26 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
US6468547B1 (en) 1996-10-30 2002-10-22 Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP1012275A1 (en) 1997-01-31 2000-06-28 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US20020076695A1 (en) 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20020192211A1 (en) 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2357525A1 (en) 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of her-2/neu
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
JP3485252B2 (ja) 1999-06-16 2004-01-13 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AR024464A1 (es) * 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP2977063A1 (en) 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DE60033658T2 (de) 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
CA2383615A1 (en) 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
WO2001053354A2 (en) 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
CA2397349A1 (en) 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6767541B2 (en) 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
CA2404919A1 (en) 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
HK1054200A1 (zh) 2000-05-15 2003-11-21 法玛西雅意大利公司 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
AU2001295002B2 (en) 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
NZ546251A (en) 2000-12-01 2008-01-31 Response Genetics Inc Method of determining epidermal growth factor receptor gene expression in a parafin embedded tiasue sample and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040138160A1 (en) 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
AU2002315306B2 (en) 2001-05-08 2007-05-17 Merck Patent Gmbh Combination therapy using anti-EGFR antibodies and anti-hormonal agents
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US20030068318A1 (en) 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20030096823A1 (en) 2001-11-16 2003-05-22 Beryl Asp Method for the treatment of cardiotoxicity induced by antitumor compounds
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030175845A1 (en) 2002-03-13 2003-09-18 Kalbag Suresh M. Use of sulfitolysis in high performance peptide mapping
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
ITTO20020340A1 (it) 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
US20030202973A1 (en) 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US20040013297A1 (en) 2002-07-18 2004-01-22 Roger Lo Method for performing color gamut compression
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1572972A4 (en) 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
WO2004053497A2 (en) 2002-12-11 2004-06-24 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
EP1597558A2 (en) 2003-01-08 2005-11-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004087207A2 (en) 2003-03-27 2004-10-14 Georgetown University Method for inducing apoptosis and aneuploidy regression in cancer cells
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
US7341195B2 (en) * 2003-10-01 2008-03-11 Cimino Deirdre M System and method for targeted education and advertising
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070021435A1 (en) 2005-06-10 2007-01-25 Gaul Michael D Aminopyrimidines as kinase modulators
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007259171A1 (en) 2006-06-05 2007-12-21 F. Hoffmann-La Roche, Ag Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
WO2008064884A1 (en) 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
AU2008258859A1 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CL2009000545A1 (es) 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合

Also Published As

Publication number Publication date
KR20090115980A (ko) 2009-11-10
PE20090681A1 (es) 2009-06-10
TW200900698A (en) 2009-01-01
JP2014240434A (ja) 2014-12-25
MX2009008981A (es) 2009-09-02
US20100008975A1 (en) 2010-01-14
CN103432580A (zh) 2013-12-11
US20110246399A1 (en) 2011-10-06
AU2008223069B2 (en) 2012-12-13
AU2008223069A1 (en) 2008-09-12
WO2008109440A2 (en) 2008-09-12
CN101680897A (zh) 2010-03-24
US20130039909A1 (en) 2013-02-14
BRPI0808418A2 (pt) 2014-07-22
JP2010520225A (ja) 2010-06-10
NZ578824A (en) 2012-03-30
IL199989A (en) 2015-09-24
WO2008109440A3 (en) 2009-04-23
DK2132573T3 (da) 2014-07-14
CL2008000614A1 (es) 2008-09-05
TWI352199B (en) 2011-11-11
PL2132573T3 (pl) 2014-09-30
KR20150039212A (ko) 2015-04-09
EP2899541A1 (en) 2015-07-29
JP2015187172A (ja) 2015-10-29
EP2132573A2 (en) 2009-12-16
US8940302B2 (en) 2015-01-27
CN101680897B (zh) 2013-11-13
WO2008109440A8 (en) 2009-12-10
JP2013166784A (ja) 2013-08-29
US7981418B2 (en) 2011-07-19
EP2132573B1 (en) 2014-04-23
CA2677108A1 (en) 2008-09-12
US20110245103A1 (en) 2011-10-06
IL199989A0 (en) 2010-04-15
HK1141586A1 (en) 2010-11-12
CO6220870A2 (es) 2010-11-19
US20150111211A1 (en) 2015-04-23
AR065589A1 (es) 2009-06-17
SI2132573T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
EP2132573B1 (en) Predicting response to a her dimerisation inhbitor based on low her3 expression
ES2440481T3 (es) Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
EP1846030B1 (en) Fixed dosing of her antibodies
BRPI0712077A2 (pt) prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa
WO2011146568A1 (en) Predicting response to a her inhibitor
AU2013200248A1 (en) Predicting response to a HER dimerisation inhibitor based on low HER3 expression
HK1141586B (en) Predicting response to a her dimerisation inhibitor based on low her3 expression
HK1165303A (en) Extending time to disease progression or survival in cancer patients
HK1105589A (en) Fixed dosing of her antibodies